Reversing an earlier decision, European regulators recommended that an Alzheimer’s therapy from Eisai and Biogen should be ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer ...

The European Medicines Agency has revealed a list of five cities that are preferred as its new location by staff after Brexit, following warnings of a public health disaster if EU leaders pick the ...

The European Centre for Disease Prevention and Control (ECDC) said consumption of antibiotics in the EU had increased by one ...

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on the results from the LAURA phase III trial, which were published in The ...

The European Medicines Agency said Thursday that its committee evaluating medical products has recommended partial approval ...

The UK’s chief Brexit negotiator, minister David Davis will fight to keep the European Medicines Agency in London, despite the country leaving the EU. The Financial Times has reported that the ...

Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced a positive opinion has been received from the Committee for Medicinal ...

MEDIA RELEASEAfqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD)One ...

today announced that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT05, ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and (Nasdaq: BIIB, Corporate headquarters: Cambridge, ...